所有错配修复缺陷型子宫内膜癌都一样吗?一项大型回顾性三级中心经验
该回顾性研究纳入1171例手术分期的子宫内膜癌患者,其中362例(30.9%)为错配修复缺陷(MMRd),按免疫组化及MLH1启动子甲基化分析分为MLH1高甲基化、MLH1未甲基化及非MLH1三组;MLH1高甲基化组临床病理特征更具侵袭性,但三组无事件生存期(EFS)无显著差异,MLH1高甲基化组在晚期/转移阶段呈现预后较差的趋势。
要点
- 在1171例手术分期子宫内膜癌中,362例(30.9%)为MMRd。
- MLH1高甲基化组较其他MMRd亚组初诊年龄更大、BMI更高、肿瘤更大、肌层浸润更深、淋巴血管间隙浸润更明显、早期及低危比例更低。
- 三组MMRd亚型间EFS无显著差异,MLH1高甲基化组在晚期/转移阶段呈预后较差趋势。
核心结论
- MLH1高甲基化MMRd子宫内膜癌较其他MMRd亚组表现出更具侵袭性的临床病理特征;尽管MLH1高甲基化亚组观察到EFS较差的提示性趋势(尤其在晚期阶段),但MMRd亚型间未检测到预后显著差异。
研究设计与样本
- 回顾性纳入接受手术分期的子宫内膜癌患者,所有患者均行免疫组化评估MMR及p53状态。
- 对免疫组化MLH1阴性且为MMRd的患者行MLH1启动子甲基化分析。
- 将MMRd人群分为三组:MLH1高甲基化(MLH1-HyMet)、MLH1未甲基化(MLH1-UnMet)、单独MSH2和/或MSH6或PMS2免疫组化阴性(非MLH1)。
- 共1171例患者接受手术分期及免疫组化评估,其中362例(30.9%)为MMRd并纳入分析。
- 362例MMRd患者中,MLH1-HyMet占59.7%(n=216),MLH1-UnMet占11%(n=40),非MLH1占29.3%(n=106)。
主要发现
- 与MLH1-UnMet及非MLH1组相比,MLH1-HyMet组与年龄更大、BMI更高、肿瘤更大、肌层浸润更深、明显淋巴血管间隙浸润、早期及低危疾病频率更低相关。
- 比较MMRd亚型间EFS相似,即使在调整分期和肿瘤组织学后亦然。
- 可观察到MLH1-HyMet组预后较差的趋势,尤其在晚期/转移阶段。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One third of endometrial carcinomas (ECs) presents with mismatch repair deficiency (MMRd). Of these, 70 % are caused by somatic hypermethylation of MLH1 promoter; the remaining cases are determined by Lynch syndrome or double somatic inactivation of MMR genes. Although associated with good-intermediate prognosis, heterogeneity in treatment response and survival has been reported among MMRd ECs. We aim to investigate differences in pathologic aggressiveness and event-free survival (EFS) among three MMRd EC subtypes, classified by immunohistochemistry (IHC) and MLH1 methylation analysis. METHODS: Subjects undergone surgical staging for EC were retrospectively included. IHC analysis was performed in all patients to assess MMR and p53 status. Methylation analysis was performed in MMRd patients with IHC-negative MLH1. The MMRd population was classified into: 1)MLH1-hypermethylated (MLH1-HyMet); 2)MLH1-unmethylated (MLH1-UnMet); 3)IHC-negative MSH2 and/or MSH6 or PMS2 alone (non-MLH1). RESULTS: Of 1171 patients undergoing surgical staging and IHC assessment, 362 (30.9 %) were classified as MMRd and included in the analysis. Among these, 59.7 % (n = 216) were MLH1-HyMet, 11 % (n = 40) MLH1-UnMet, and 29.3 % (n = 106) non-MLH1. Compared to MLH1-UnMet and non-MLH1, MLH1-HyMet was associated with older age, higher BMI, larger tumor size, deeper myometrial invasion, substantial lymphovascular space invasion, lower frequency of early-stage and low-risk disease. EFS was similar when comparing the MMRd subtypes, even after adjusting for stage and tumor histology. However, a trend of MLH1-HyMet toward poorer prognosis can be observed, particularly in the advanced/metastatic setting. CONCLUSIONS: MLH1-hypermethylated MMRd ECs display more aggressive clinicopathologic features compared to the other MMRd subgroups. However, although a suggestive trend toward poorer EFS was observed in the hypermethylated subset, particularly in the advanced setting, no significant differences in prognosis were detected among the MMRd subtypes.
引用
- Capasso I, Perrone E, Duranti S, et al. Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience. Eur J Cancer. 2025. PMID: 40058269. doi:10.1016/j.ejca.2025.115344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。